EE260 Cost-Effectiveness Analysis of Daratumumab Triplet Therapy Vs Carfilzomib Duplet Therapy in Patients with Relapsed or Refractory Multiple Myeloma in Egypt from Payer Perspective
Abstract
Authors
G. Elsisi M. Elattar N. Eldesouky